IGC Pharma announced that its Phase 2 CALMA trial for the Alzheimer’s agitation candidate IGC‑AD1 has reached 70 % of its planned enrollment target, enrolling 102 of the 146 participants the study is designed to recruit. The trial is active at 23 sites across 26 locations in the United States and Canada, reflecting a broad geographic footprint that supports the company’s hybrid recruitment strategy combining site‑driven outreach with precision digital campaigns.
Reaching 70 % enrollment is a critical operational milestone that signals the company’s recruitment strategy is on track. CEO Ram Mukunda noted that the milestone “reflects improving execution and site productivity across our network” and that enrollment is the final operational gate before the study can move to database lock and topline analysis. The hybrid approach has accelerated patient access and is expected to keep the trial on schedule for a mid‑2026 read‑out window.
The company’s goal is to complete the trial before its estimated 12‑month cash runway expires. While the exact cash balance is not disclosed, IGC Pharma has historically raised capital through private placements and ATM offerings to fund its clinical programs and has maintained a focus on cost control to extend its runway. Completing enrollment on time will reduce the risk of additional financing needs and position the company to advance IGC‑AD1 toward regulatory submission if efficacy data are favorable.
IGC Pharma’s financial profile underscores the importance of this milestone. The company has reported net losses in prior periods and has relied on external capital to support its research and development pipeline. The successful enrollment progress mitigates the risk of a cash crunch that could delay the trial or force a shift in resource allocation. By keeping the study on schedule, IGC Pharma preserves its ability to pursue further development of IGC‑AD1 and other AI‑driven candidates in its pipeline.
The Alzheimer’s agitation market remains underserved, with only one FDA‑approved therapy and limited alternatives. IGC‑AD1, a partial CB1 receptor agonist with anti‑inflammatory properties, has shown promising reductions in agitation in interim analyses and may offer disease‑modifying effects. The company’s integration of AI through its MINT‑AD platform enhances patient targeting and trial efficiency, positioning IGC‑AD1 as a differentiated option in a competitive landscape.
Overall, the 70 % enrollment milestone demonstrates that IGC Pharma’s recruitment strategy is effective and that the company is on track to meet its clinical and financial objectives. Successful completion of the CALMA trial will be a pivotal step toward bringing a potentially safer and more effective therapy for Alzheimer’s agitation to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.